BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Whipple C, Korc M. Targeting angiogenesis in pancreatic cancer: rationale and pitfalls. Langenbecks Arch Surg. 2008;393:901-910. [PMID: 18210149 DOI: 10.1007/s00423-008-0280-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Zhao S, Ma D, Dai H, Yuan F, Wang Z. Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells. Arch Gynecol Obstet 2011;284:1533-41. [DOI: 10.1007/s00404-011-1891-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Zhao C, Pu Y, Zhang H, Hu X, Zhang R, He S, Zhao Q, Mu B. IL10-modified Human Mesenchymal Stem Cells inhibit Pancreatic Cancer growth through Angiogenesis Inhibition. J Cancer 2020;11:5345-52. [PMID: 32742480 DOI: 10.7150/jca.38062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol 2016; 22(2): 776-789 [PMID: 26811624 DOI: 10.3748/wjg.v22.i2.776] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
4 Gore J, Korc M. Pancreatic cancer stroma: friend or foe? Cancer Cell. 2014;25:711-712. [PMID: 24937454 DOI: 10.1016/j.ccr.2014.05.026] [Cited by in Crossref: 114] [Cited by in F6Publishing: 114] [Article Influence: 14.3] [Reference Citation Analysis]
5 Khan MA, Srivastava SK, Bhardwaj A, Singh S, Arora S, Zubair H, Carter JE, Singh AP. Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications. Oncotarget 2015;6:39140-50. [PMID: 25970774 DOI: 10.18632/oncotarget.3784] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
6 Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U. Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer. 2014;110:172-182. [PMID: 24178759 DOI: 10.1038/bjc.2013.681] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 8.7] [Reference Citation Analysis]
7 Nielsen MFB, Mortensen MB, Detlefsen S. Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 2016; 22(9): 2678-2700 [PMID: 26973408 DOI: 10.3748/wjg.v22.i9.2678] [Cited by in CrossRef: 140] [Cited by in F6Publishing: 126] [Article Influence: 23.3] [Reference Citation Analysis]
8 Bi Y, Lei X, Chai N, Linghu E. NOX4: a potential therapeutic target for pancreatic cancer and its mechanism. J Transl Med 2021;19:515. [PMID: 34930338 DOI: 10.1186/s12967-021-03182-w] [Reference Citation Analysis]
9 Gutknecht MF, Seaman ME, Ning B, Cornejo DA, Mugler E, Antkowiak PF, Moskaluk CA, Hu S, Epstein FH, Kelly KA. Identification of the S100 fused-type protein hornerin as a regulator of tumor vascularity. Nat Commun 2017;8:552. [PMID: 28916756 DOI: 10.1038/s41467-017-00488-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
10 Dragovich T, Laheru D, Dayyani F, Bolejack V, Smith L, Seng J, Burris H, Rosen P, Hidalgo M, Ritch P. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemother Pharmacol. 2014;74:379-387. [PMID: 24939212 DOI: 10.1007/s00280-014-2499-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
11 Vascotto C, Fishel ML. Blockade of Base Excision Repair. DNA Repair in Cancer Therapy. Elsevier; 2012. pp. 29-53. [DOI: 10.1016/b978-0-12-384999-1.10003-4] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Maity G, Mehta S, Haque I, Dhar K, Sarkar S, Banerjee SK, Banerjee S. Pancreatic tumor cell secreted CCN1/Cyr61 promotes endothelial cell migration and aberrant neovascularization. Sci Rep. 2014;4:4995. [PMID: 24833309 DOI: 10.1038/srep04995] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
13 Craven KE, Gore J, Korc M. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Lett 2016;381:201-10. [PMID: 26723874 DOI: 10.1016/j.canlet.2015.11.047] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
14 Koay EJ, Amer AM, Baio FE, Ondari AO, Fleming JB. Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers. Cancer Lett. 2016; Epub ahead of print. [PMID: 26806807 DOI: 10.1016/j.canlet.2015.12.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
15 Kim SJ, Lee Y, Kim NY, Hwang Y, Hwang B, Min J, Koh SS. Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability. Oncogene 2013;32:3638-47. [DOI: 10.1038/onc.2012.366] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zhang Y, Huang Z, Cheng J, Pan H, Lin T, Shen X, Chen W, Chen Q, Gu C, Mao Q, Liang Y. Platelet-Vesicles-Encapsulated RSL-3 Enable Anti-Angiogenesis and Induce Ferroptosis to Inhibit Pancreatic Cancer Progress. Front Endocrinol 2022;13:865655. [DOI: 10.3389/fendo.2022.865655] [Reference Citation Analysis]
17 Gao Y, Jia Z, Kong X, Li Q, Chang DZ, Wei D, Le X, Suyun H, Huang S, Wang L. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res. 2011;71:5182-5193. [PMID: 21673052 DOI: 10.1158/0008-5472.CAN-10-2016] [Cited by in Crossref: 60] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
18 Qian W, Li J, Chen K, Jiang Z, Cheng L, Zhou C, Yan B, Cao J, Ma Q, Duan W. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sci. 2018;208:253-261. [PMID: 30053447 DOI: 10.1016/j.lfs.2018.07.046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
19 Lei F, Xi X, Batra SK, Bronich TK. Combination Therapies and Drug Delivery Platforms in Combating Pancreatic Cancer. J Pharmacol Exp Ther 2019;370:682-94. [PMID: 30796131 DOI: 10.1124/jpet.118.255786] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
20 Cui R, Yue W, Lattime EC, Stein MN, Xu Q, Tan XL. Targeting tumor-associated macrophages to combat pancreatic cancer. Oncotarget 2016;7:50735-54. [PMID: 27191744 DOI: 10.18632/oncotarget.9383] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
21 Yako YY, Brand M, Smith M, Kruger D. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report. Pancreatology 2017;17:438-44. [PMID: 28377069 DOI: 10.1016/j.pan.2017.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
22 Jia Z, Gao Y, Wang L, Li Q, Zhang J, Le X, Wei D, Yao JC, Chang DZ, Huang S, Xie K. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res 2010;70:1111-9. [PMID: 20086170 DOI: 10.1158/0008-5472.CAN-09-3282] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
23 Klotz LV, Eichhorn ME, Schwarz B, Seeliger H, Angele MK, Jauch KW, Bruns CJ. Targeting the vasculature of visceral tumors: novel insights and treatment perspectives. Langenbecks Arch Surg 2012;397:569-78. [PMID: 22415155 DOI: 10.1007/s00423-012-0946-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]